Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes

Metabolic syndrome (MetS) is a complex interplay of interrelated metabolic derangements, including insulin resistance, dyslipidemia, central adiposity, and hypertension, thereby markedly amplifying the predisposition to type 2 diabetes mellitus (T2DM) and cardiovascular morbidities. Chromium (Cr), an indispensable trace element, has garnered scientific interest for its putative role in augmenting insulin sensitivity and modulating glucose metabolism. Chromium deficiency has been linked with insulin resistance and diabetes mellitus. A cycle of low chromium, defective glucose metabolism, and further loss of chromium is documented. Chromium supplementation has been associated with encouraging improvements in insulin sensitivity. It may enhance insulin signaling, regulate lipid metabolism, and mitigate obesity-related dysfunctions. However, its therapeutic efficacy remains debated due to inconsistent clinical outcomes and study variations. This comprehensive review delves into the implications of chromium supplementation, particularly chromodulin, in the context of MetS and its associated pathological sequelae. In conclusion, chromium (Cr) enhances insulin sensitivity by directly activating the insulin receptor kinase, which lowers the required insulin concentration for maximal cellular response and improves glucose uptake and storage. Synthesis of the evidence shows that Chromium (Cr) supplementation significantly benefits individuals with chromium deficiency or diabetes, improving glucose homeostasis and insulin sensitivity. This highlights the importance of baseline metabolic status in the effectiveness of Cr as a treatment, indicating that targeted interventions may be needed for optimal results in those with metabolic disturbances.